1-(3-chloropropoxy)-2-(1-methylethoxy)benzene | 117022-42-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(3-chloropropoxy)-2-(1-methylethoxy)benzene
• 英文别名: 1-(3-chloropropoxy)-2-isopropoxybenzene；1-chloro-3-[2-(1-methylethoxy)phenoxy]propane；1-(3-chloropropoxy)-2-propan-2-yloxybenzene
• CAS: 117022-42-1
• 化学式: C₁₂H₁₇ClO₂
• 分子量: 228.719
• InChiKey: XHXFQOVACQQRFI-UHFFFAOYSA-N

物化性质

• 沸点：
  307.5±17.0 °C(Predicted)
• 密度：
  1.062±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  双(4-氟苯基)-哌啶-4-基甲醇 、 1-(3-chloropropoxy)-2-(1-methylethoxy)benzene 在 sodium carbonate 、 potassium iodide 作用下， 以 正丁醇 为溶剂， 以58%的产率得到α,α-Bis(4-fluorophenyl)-1-[3-[2-(1-methylethoxy)phenoxy)propyl]-4-piperidinemethanol
  参考文献：
  名称：

  4-（二芳基羟甲基）-1- [3-（芳氧基）丙基]哌啶及结构相关化合物的合成及抗过敏活性。

  摘要：

  合成了一系列的4-（二芳基羟甲基）-1- [3-（芳氧基）丙基]哌啶，并评估了其抗过敏活性。几种类似物在被动足过敏症（PFA）检测中具有有效活性，PFA检测是一种IgE介导的模型，可用于检测具有抗过敏活性的化合物。特别是1- [4- [3- [4- [双（4-氟苯基）羟甲基] -1-哌啶基]丙氧基] -3-甲氧基苯基]乙酮（1，AHR-5333）比奥沙米特和特非那定在这种测定。

  DOI：

  10.1021/jm00121a022
• 作为产物：
  描述：

  2-异丙氧基苯酚 、 1-溴-3-氯丙烷 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 24.0h， 以62%的产率得到1-(3-chloropropoxy)-2-(1-methylethoxy)benzene
  参考文献：
  名称：

  4-（二芳基羟甲基）-1- [3-（芳氧基）丙基]哌啶及结构相关化合物的合成及抗过敏活性。

  摘要：

  合成了一系列的4-（二芳基羟甲基）-1- [3-（芳氧基）丙基]哌啶，并评估了其抗过敏活性。几种类似物在被动足过敏症（PFA）检测中具有有效活性，PFA检测是一种IgE介导的模型，可用于检测具有抗过敏活性的化合物。特别是1- [4- [3- [4- [双（4-氟苯基）羟甲基] -1-哌啶基]丙氧基] -3-甲氧基苯基]乙酮（1，AHR-5333）比奥沙米特和特非那定在这种测定。

  DOI：

  10.1021/jm00121a022

文献信息

• Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a
  申请人：A. H. Robins Company, Incorporated

  公开号：US04950674A1

  公开（公告）日：1990-08-21

  A method of inhibiting Type 1 allergic responses in a living animal body with substituted heterocyclic amines is disclosed wherein the active agents are expressed generally by the formula which includes certain known and certain known compounds: ##STR1## wherein P is zero, one or two; m is one to six inclusive; A is selected from hydrogen, hydroxy or cyano; d is zero or one; Q is --CH--, CH.sub.2 -- or ##STR2## n is zero or one and when Q is --CH-- and n is one, a double bond is formed with one of the adjacent carbons but not both at the same time, and when n and d are zero at the same time, a double bond is formed between the .alpha. carbon and a carbon of the central heterocyclic amine ring; Ar, D and R are selected from phenyl, substituted phenyl, pyridinyl, thienyl, furanyl or naphthyl and in addition, R may have the values benzyl, substituted benzyl, cycloalkyl or loweralkyl and D may additionally have the values: 2H-1-benzopyran-2-one,4-oxo-4H-1-benzopyran-2-carboxylic acid loweralkyl ester, 2,3-dihydro-4H-1-benzopyran-4-one, 1,4-benzodioxanloweralkyl-2-yl or 1,1'-biphenyl-4-yl and the pharmaceutically acceptable salts thereof.

  揭示了一种利用取代杂环胺抑制活体动物体内的1型过敏反应的方法，其中活性剂通常由以下公式表示：其中P为零、一或二；m为一到六（包括六）；A选自氢、羟基或氰基；d为零或一；Q为--CH--、CH.sub.2--或n为零或一，当Q为--CH--且n为一时，与相邻碳之一形成双键，但不同时与两个相邻碳形成双键；当n和d同时为零时，在中心杂环胺环的α碳和一个碳之间形成双键；Ar、D和R选自苯基、取代苯基、吡啶基、噻吩基、呋喃基或萘基，此外，R可能具有苄基、取代苄基、环烷基或较低烷基的值，D还可能具有以下值：2H-1-苯并吡喃-2-酮、4-氧代-4H-1-苯并吡喃-2-羧酸较低烷基酯、2,3-二氢-4H-1-苯并吡喃-4-酮、1,4-苯并二氧杂环较低烷基-2-基或1,1'-联苯基-4-基，以及其药学上可接受的盐。
• INDOLEAMINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES
  申请人：Kolaczkowski Marcin

  公开号：US20140121216A1

  公开（公告）日：2014-05-01

  Indoleamine derivatives of formula (IA), R 1 represents benzyl unsubstituted or substituted with halogen atom, —OH, or C 1 -C 3 -alkyl; phenylsulphonyl unsubstituted or substituted in the phenyl ring with halogen atom, —OH or C 1 -C 3 -alkyl; G 1 represents phenoxyalkyl, heteroaryloxyalkyl- or heterocyclyloxyalkyl-piperazine moiety; and pharmaceutically acceptable salts and solvates thereof. The compounds may be useful for the treatment and/or prevention of the central nervous system disorders.

  公式（IA）的吲哚胺衍生物，其中R1代表苄基未取代或取代为卤原子，-OH，或C1-C3-烷基；苯磺酰未取代或取代为苯环中的卤原子，-OH或C1-C3-烷基；G1代表苯氧基烷基，杂环氧基烷基-或杂环氧基烷基-哌嗪基；以及其药学上可接受的盐和溶剂合物。这些化合物可能对治疗和/或预防中枢神经系统疾病有用。
• [EN] INDOLEAMINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES<br/>[FR] DÉRIVÉS INDOLÉAMINE UTILISÉS DANS LE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL
  申请人：ADAMED SP ZOO

  公开号：WO2013001499A1

  公开（公告）日：2013-01-03

  Indoleamine derivatives of formula (IA), wherein R1 represents benzyl unsubstituted or substituted with halogen atom, -OH, or C1-C3-alkyl; phenylsulphonyl unsubstituted or substituted in the phenyl ring with halogen atom, -OH or C1-C3-alkyl; G1 represents phenoxyalkyl, heteroaryloxyalkyl- or heterocyclyloxyalkyl-piperazine moiety; and pharmaceutically acceptable salts and solvates thereof. The compounds may be useful for the treatment and/or prevention of the central nervous system disorders.

  公式（IA）的吲哚胺衍生物，其中R1表示苯甲基未取代或取代有卤素原子，-OH或C1-C3-烷基；苯磺酰基未取代或在苯环中取代有卤素原子，-OH或C1-C3-烷基；G1表示苯氧基烷基，杂环氧基烷基-或杂环氧基烷基-哌嗪基；以及其药学上可接受的盐和溶解物。该化合物可用于治疗和/或预防中枢神经系统疾病。
• Effects of chronic mild stress on rats selectively bred for behavior related to bipolar disorder and depression
  作者：Ryan Murray、Katherine A. Boss-Williams、Jay M. Weiss

  DOI：10.1016/j.physbeh.2013.05.042

  日期：2013.7

  To test the possibility that chronic mild stress (CMS) might be unreliable in producing its often-intended outcome (i.e., decreased preference for sucrose, hypothesized to represent depression-relevant anhedonia) because it is typically applied to "normal" rats, a CMS procedure was applied to rats that may possess genetic susceptibility to affective disorders, having had been selectively-bred to show behavior indicative of such disorders. These rat lines were: Hyperactive (HYPER) rats, which show characteristics of bipolar disorder, Swim-test Susceptible (SUS) and Swim-test Resistant (RES) rats, being susceptible or resistant to effects of stress in the swim test, Swim High-active (SwHi) and Swim Low-active (SwLo) rats, which innately show high or low activity in the swim test These selectively-bred lines were compared to normal, non-selectively bred (NS) rats. During CMS, HYPER rats, both females and males, as well as RES and SwHi rats, showed reduced consumption of a palatable 2% sucrose solution, and reduced preference for sucrose (vs. water) in comparison to non-stressed rats (no CMS) of the same lines. In contrast, CMS produced no decrease in sucrose consumption or in preference for sucrose in normal NS rats, and actually a caused a slight increase in sucrose consumption and preference in male NS rats. Other measures that indicate depression - food intake and motor activity in the home cage - were also assessed. SwLo and SwHi showed greater sensitivity to having their home-cage ambulatory activity reduced by CMS than did NS rats, but no other such differences relative to NS rats were seen for these other measures; thus, changes in sucrose intake or preference could not be explained by a change in caloric intake. These results suggest that the genetic attributes of animals can influence the outcome of CMS, and that the application of CMS to normal, non-selected rats may account, at least in part, for the unreliability of CMS in decreasing consumption of palatable substances and decreasing preference for such substances. (C) 2013 Published by Elsevier Inc.
• US4950674A
  申请人：——

  公开号：US4950674A

  公开（公告）日：1990-08-21